Andere Kunden interessierten sich auch für
![Drug Interactions of Sitagliptin with Anti-retroviral Drugs in Animals]( "Drug Interactions of Sitagliptin with Anti-retroviral Drugs in Animals")
Drug Interactions of Sitagliptin with Anti-retroviral Drugs in Animals42,99 €![Estudo de dissolução intrínseca de Efavirenz]( "Estudo de dissolução intrínseca de Efavirenz")
Estudo de dissolução intrínseca de Efavirenz40,99 €![H.Pylori: An Enemy Inside Human G.I.T]( "H.Pylori: An Enemy Inside Human G.I.T")
H.Pylori: An Enemy Inside Human G.I.T32,99 €![Ivermectin for alcohol use disorders]( "Ivermectin for alcohol use disorders")
Ivermectin for alcohol use disorders36,99 €![Investigation of solid-state diversity of Amantadine Hydrochloride]( "Investigation of solid-state diversity of Amantadine Hydrochloride")
Investigation of solid-state diversity of Amantadine Hydrochloride32,99 €![Wound Healing Properties of some Indigenous Ghanaian Plants]( "Wound Healing Properties of some Indigenous Ghanaian Plants")
Wound Healing Properties of some Indigenous Ghanaian Plants51,99 €![Tolerance and Physical Dependence for Tramadol Hcl]( "Tolerance and Physical Dependence for Tramadol Hcl")
Tolerance and Physical Dependence for Tramadol Hcl40,99 €
Efavirenz was approved by the Food and Drug Administration (FDA) on September 21, 1998, making it the 14th approved antiretroviral drug. Efavirenz (brand name sustiva) is an orally active, non-nucleoside reverse transcriptase inhibitor (nnRTI) that is specific for human immunodeficiency virus, type1 (HIV-1). Efavirenz has a terminal half-life of 52 76 hours after a single dose and 40 55 hours after multiple dosing. It is used together with other antiretrovirals to delay the progression of HIV infection. By doing this, your immune system should improve (increase in CD4+ count) and you will be better protected against infections. Efavirenz does not cure AIDS or completely kill the HIV virus, but helps to prevent further damage by slowing down the production of new viruses. Efavirenz was combined with the popular HIV medication Truvada and approved by the FDA in July of 2006, under the brand name Atripla. Efavirenz is the preferred non-nucleoside reverse transcriptase inhibitor for first-line antiretroviral treatment in many countries.